UK-based Quantum Farma, in strategic partnership with FarmaUSA, promises a ‘milestone’ in Brazil’s pharmacy market with the release of two new innovative cannabis treatments.
Specialising in bringing pharmaceutical-grade cannabinoid containing products to Latin American patients, the UK company Quantum Farma is working in partnership with FarmaUSA, which specialises in the manufacture and import of cannabinoid medicines in Brazil, to launch two new cannabis treatments in the Latin American market.
New cannabinoid-based medicines
The two innovative drugs that were launched in July are Medrosan Forte, which has a high concentration of THC, and Medrosan Extra, which includes cannabigerol (CBG). The new cannabis products are organically produced using pure genetic seeds, are developed by Swiss company Medropharm and are audited by the Swiss Medicines Agency.
Medrosan Forte combines 75mg of CBD and 9mg of THC, making it one of the highest dosages of THC in a full spectrum cannabis product in Brazil. Medrosan Extra contains 50mg of CBG and 12.5mg of CBD. According to the companies, Medrosan Extra is a full spectrum product as it comes from a plant with pure genetics, which produces undetectable amounts of THC. They say possible applications include being used as an anti-inflammatory and powerful muscle relaxant, in addition to being ideal for people who cannot use THC.
Karan Madan, CEO of Quantum Farma, commented: “Quantum Farma is committed to bringing high quality Swiss GMP medicines to Latin America. We are excited to contribute to the access of Medrosan Forte and Extra in all regions of Brazil.”
“These releases reinforce FarmaUSA’s mission, which is to provide exclusive, innovative and world-renowned treatments for the national territory, contributing to a better quality of life for patients and offering all the support of information and knowledge so that doctors feel safe in their prescriptions,” added Helder Dário Colmenero, Technical Director of FarmaUSA.
[activecampaign form=31]
